[144] Standex International Corporation SEC Filing

Rhea-AI Filing Summary

Standex International Corporation's Form 144 notifies a proposed sale of 16,000 shares of common stock on the NYSE through UBS Financial Services with an approximate aggregate market value of $3,200,000, and an indicated sale date of 08/13/2025. The filing lists 12,068,262 shares outstanding, which places the proposed sale at roughly 0.13% of the outstanding common stock.

The securities were acquired by the selling person through vested restricted stock units: 4,206 shares on 08/23/2023, 6,794 shares on 09/06/2023, and 5,000 shares on 09/06/2022. The form reports Nothing to Report for sales in the past three months. Several identifying fields in the filing (for example, filer CIK and issuer name/address sections) are blank or not populated in the provided text.

Positive

• Full acquisition history provided: RSU vest dates and share amounts are listed for all 16,000 shares.
• No sales in prior three months: The form states "Nothing to Report" for securities sold during the past three months.

Negative

• Large insider sale value: Proposed aggregate market value is $3,200,000, which some investors may view negatively.
• Incomplete identifying information: Filer CIK, issuer name/address and other contact fields are blank or not populated in the provided text.

Insights

Securities Analyst

TL;DR: Routine Rule 144 insider sale of 16,000 shares valued at $3.2M; size is small relative to outstanding shares and likely not market-moving.

The Form 144 discloses a planned sale of 16,000 common shares via UBS on the NYSE for an aggregate value of $3,200,000. Against the stated 12,068,262 shares outstanding, the position represents approximately 0.13% of outstanding stock, suggesting limited direct market impact. The securities were acquired via RSU vesting on three dates in 2022 and 2023, indicating the sale is of previously vested compensation rather than newly issued shares. The filer reports no sales in the prior three months, which reduces immediate pattern concerns. Overall impact: neutral.

Corporate Governance Expert

TL;DR: Disclosure shows insider RSU-derived sale but the filing omits several identifying fields and a plan adoption date, limiting transparency.

The filing documents clear acquisition history (RSU vests totaling 16,000 shares) and a proposed broker-facilitated sale on 08/13/2025. However, key administrative fields in the provided text (such as filer CIK and issuer contact details) appear empty, and no date of a Rule 10b5-1 plan adoption is provided in the visible content. The filer does represent that they are unaware of undisclosed material adverse information. From a governance perspective, the transaction is routine but the missing administrative details reduce the completeness of the public disclosure.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. Eleven Madison Avenue 4th Floor New York NY 10010	16000	3200000.00	12068262	08/13/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/23/2023	RSU Vest	Issuer			4206	08/23/2023	NA
Common	09/06/2023	RSU Vest	Issuer			6794	09/06/2023	NA
Common	09/06/2022	RSU Vest	Issuer			5000	09/06/2022	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Standex (SXI) report in this Form 144?

The filing reports a proposed sale of 16,000 common shares on the NYSE through UBS Financial Services with an aggregate market value of $3,200,000 and an approximate sale date of 08/13/2025.

How were the 16,000 shares acquired?

All shares were acquired via RSU vesting: 4,206 on 08/23/2023, 6,794 on 09/06/2023, and 5,000 on 09/06/2022.

Does the filing show any securities sold in the past three months for SXI?

No. The filing section for securities sold during the past three months states "Nothing to Report".

What percentage of outstanding shares does the proposed sale represent?

Based on the filing's 12,068,262 shares outstanding, 16,000 shares represent about 0.13% of outstanding common stock.

Is there a Rule 10b5-1 plan adoption date provided?

No plan adoption date is provided in the visible filing content; the form includes a field for that date but it is not populated in the provided text.